Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4+ T cells to reduce the latent HIV+ cell reservoir.,Medical Microbiology and Immunology

当前位置： X-MOL 学术 › Med. Microbiol. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4+ T cells to reduce the latent HIV+ cell reservoir.
Medical Microbiology and Immunology ( IF 5.4 ) Pub Date : 2020-09-12 , DOI: 10.1007/s00430-020-00692-0
Lea Patasic ₁ , Janna Seifried _{1,

2} , Valerie Bezler ₃ , Marcell Kaljanac ₃ , Irene C Schneider ₄ , Heike Schmitz ₁ , Christiane Tondera ₁ , Jessica Hartmann ₄ , Andreas Hombach ₅ , Christian J Buchholz ₄ , Hinrich Abken _{3,

5} , Renate König _{1,

6,

7} , Klaus Cichutek _{1,

4,

6}

Affiliation

Chimeric Antigen Receptor (CAR)-redirected T cells show great efficacy in the patient-specific therapy of hematologic malignancies. Here, we demonstrate that a DARPin with specificity for CD4 specifically redirects and triggers the activation of CAR engineered T cells resulting in the depletion of CD4⁺ target cells aiming for elimination of the human immunodeficiency virus (HIV) reservoir.

中文翻译：